Collegium Pharmaceutical EV/EBIT COLL

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2020.

Today, Oct 23, 2026: 9.4×
6-year median: 11.7×
Against its 6-year history: 27th; percentile: 0 is its lowest day, 100 its highest
6-year range: 6.7× to 70.8×
Peer median: 4.9×

Collegium Pharmaceutical's EV/EBIT is 9.4× as of Oct 23, 2026.

That is below its 6-year median of 11.7×, lower than on 73% of days in the last 6 years.

Over that time it ranged from 6.7× in Nov 2024 to 70.8× in Oct 2020.

The median for 10 large drugmakers of a similar size is 4.9×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	9.4×	7.8×	13.7×
2025	14.2×	8.8×	14.2×
2024	8.8×	6.7×	12.9×
2023	12.1×	10.4×	43.6×
2022	25.4×	10.2×	34.1×
2021	10.8×	9.8×	25.2×
2020	20.7×	19.4×	70.8×

Against its peers

Companies in Drug Manufacturers - General nearest Collegium Pharmaceutical's size, closest first, today.

Company	EV/EBIT
COLLCollegium Pharmaceutical	9.4×
ABUSArbutus Biopharma	4.9×
CRMDCorMedix	2.3×
ZVRAZevra Therapeutics	2.9×
IRWDIronwood Pharmaceuticals	3.5×
PBYIPuma Biotechnology	15.6×
AMPHAmphastar Pharmaceuticals	12.2×
ARVNArvinas	n/m
OMEROmeros	n/m
PCRXPacira BioSciences	7.6×
ANABAnaptysbio	n/m
Peer median	4.9×

Where Collegium Pharmaceutical ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Collegium Pharmaceutical

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.